Opus Genetics Relocates Principal Executive Offices
Ticker: IRD · Form: 8-K · Filed: Dec 19, 2025 · CIK: 1228627
Sentiment: neutral
Topics: corporate-action, address-change
TL;DR
Opus Genetics moved its HQ to Durham, NC.
AI Summary
Opus Genetics, Inc. filed an 8-K on December 19, 2025, reporting an event on December 17, 2025. The filing indicates a change in the company's principal executive offices to 8 Davis Drive, Suite 220, Durham, NC 27713. The company previously operated under the names Ocuphire Pharma, Inc., REXAHN PHARMACEUTICALS, INC., and CORPORATE ROAD SHOW DOT COM INC.
Why It Matters
This filing signals a change in the company's operational base, which could impact its local presence and accessibility for stakeholders.
Risk Assessment
Risk Level: low — The filing reports a change of address, which is a routine administrative event with no immediate financial or operational risk.
Key Players & Entities
- Opus Genetics, Inc. (company) — Registrant
- December 17, 2025 (date) — Date of earliest event reported
- December 19, 2025 (date) — Date of Report
- 8 Davis Drive, Suite 220, Durham, NC 27713 (location) — New principal executive offices
- Ocuphire Pharma, Inc. (company) — Former company name
- REXAHN PHARMACEUTICALS, INC. (company) — Former company name
- CORPORATE ROAD SHOW DOT COM INC (company) — Former company name
FAQ
What is the new address for Opus Genetics' principal executive offices?
The new address for Opus Genetics' principal executive offices is 8 Davis Drive, Suite 220, Durham, NC 27713.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on December 17, 2025.
On what date was this 8-K filing submitted to the SEC?
This 8-K filing was submitted to the SEC on December 19, 2025.
What were some of the previous names of Opus Genetics, Inc.?
Opus Genetics, Inc. was formerly known as Ocuphire Pharma, Inc., REXAHN PHARMACEUTICALS, INC., and CORPORATE ROAD SHOW DOT COM INC.
In which state is Opus Genetics, Inc. incorporated?
Opus Genetics, Inc. is incorporated in Delaware.
Filing Stats: 462 words · 2 min read · ~2 pages · Grade level 11.5 · Accepted 2025-12-19 16:05:47
Key Financial Figures
- $0.0001 — ange on which registered Common Stock, $0.0001 par value per share IRD The Nasdaq
Filing Documents
- ef20061683_8k.htm (8-K) — 23KB
- 0001140361-25-046187.txt ( ) — 146KB
- ird-20251217.xsd (EX-101.SCH) — 4KB
- ird-20251217_lab.xml (EX-101.LAB) — 21KB
- ird-20251217_pre.xml (EX-101.PRE) — 16KB
- ef20061683_8k_htm.xml (XML) — 4KB
01
Item 8.01 Other Events. On December 17, 2025, Viatris Inc., the Company's global commercialization partner for Phentolamine Ophthalmic Solution 0.75% (Phentolamine), filed a supplemental New Drug Application (sNDA) with the U.S. Food and Drug Administration (FDA), for the treatment of presbyopia with Phentolamine. The filing is supported by the positive results from VEGA-3, the Company's second pivotal Phase 3 clinical trial with Phentolamine, which confirmed the efficacy, safety, and durability of response results previously observed in the VEGA-2 study. There can be no assurance that the FDA will accept the sNDA for filing, that the application will be deemed sufficiently complete, or that review will proceed on the anticipated timeline, if at all. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: December 19, 2025 OPUS GENETICS, INC. By: /s/ Dr. George Magrath Name: Dr. George Magrath Title: Chief Executive Officer